Material weakness
high
Filing comparison
Esperion Therapeutics, Inc. reported a material weakness in internal control
Internal control reported effective → Material weakness in internal control
Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the NASDAQ Capital Market or other adverse consequences that would materially harm our business. We have previously identified a material weakness in our internal controls over financial reporting and may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of…
Evidence
- Current state
- material_weakness
- Current state label
- Material weakness in internal control
- Direction
- newly reported
- Prior filed
- 2025-03-07
- Prior form
- 10-K
- Prior state
- effective
- Prior state label
- Internal control reported effective
- Remediation stated
- Yes
- Severity
- high
- Source
- Item 9A internal control conclusion, compared with the prior filing
- Why
- The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.